Results 31 to 40 of about 41,661 (291)

NON-GENOMIC ANDROGEN ACTION REGULATES PROLIFERATIVE/MIGRATORY SIGNALLING IN STROMAL CELLS.

Frontiers in Endocrinology, 2015
Prostate cancer is the major cause of cancer-related death among the male population of Western society, and androgen deprivation therapy represents the first line in prostate cancer treatment. However, although androgen receptor expression is maintained
Marzia eDi Donato, Pia eGiovannelli, Gustavo eCernera, Annalisa eDi Santi, Irene eMarino, Antonio eBilancio, Giovanni eGalasso, Ferdinando eAuricchio, Antimo eMigliaccio, Gabriella eCastoria   +9 more
doaj   +1 more source

Androgen Deprivation Therapy and Cardiovascular Risk [PDF]

Journal of Clinical Oncology, 2011
Purpose The potential association between androgen deprivation therapy (ADT) and cardiovascular mortality (CVM) remains controversial. This study assessed mortality outcomes in a large national registry to further elucidate the association between treatment selection and cause of mortality.
Sanoj, Punnen, Matthew R, Cooperberg, Natalia, Sadetsky, Peter R, Carroll   +3 more
openaire   +2 more sources

Androgen receptor and MYC equilibration centralizes on developmental super-enhancer

Nature Communications, 2021
Androgen receptor in prostate cancer (PCa) transcriptionally represses multiple genes including MYC. Here, the authors suggest that increased MYC in response to androgen deprivation contributes to castration-resistant PCa, while decreased MYC may ...
Haiyang Guo, Yiming Wu, Mannan Nouri, Sandor Spisak, Joshua W. Russo, Adam G. Sowalsky, Mark M. Pomerantz, Zhao Wei, Keegan Korthauer, Ji-Heui Seo, Liyang Wang, Seiji Arai, Matthew L. Freedman, Housheng Hansen He, Shaoyong Chen, Steven P. Balk   +15 more
doaj   +1 more source

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer

, 2022
Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa). Although most patients initially respond to ADT, almost all cancers eventually develop castration resistance.
Zihua Chen, Shoujiao Peng, Shangwei Zhong, Zhikang Chen, Jun-Li Luo   +4 more
core   +1 more source

Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer

Prostate Cancer, 2011
Prostate cancer is one of the most common malignancies in men. Charles Huggins and Clarence V. Hodges reported the androgen dependence of prostate cancer in 1941.
Bhavin R. Shastri, Subhashini Yaturu
doaj   +1 more source

Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.

PLoS ONE, 2021
BackgroundMen have a higher risk of death from COVID-19 than women and androgens facilitate entrance of the SARS-CoV-2 virus into respiratory epithelial cells.
Rolf Gedeborg, Johan Styrke, Stacy Loeb, Hans Garmo, Pär Stattin   +4 more
doaj   +1 more source

Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer

European Urology Open Science, 2022
The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has dramatically evolved. Monotherapy androgen deprivation therapy (ADT) with testosterone suppression alone is no longer the standard of care as multiple global phase 3 ...
Seyed Behzad Jazayeri, Lauren Folgosa Cooley, Abhishek Srivastava, Neal Shore   +3 more
doaj   +1 more source

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways [PDF]

, 2005
Prostate cancer is the second leading cause of cancer related deaths in men from the western world. Treatment of prostate cancer has relied on androgen deprivation therapy for the past 50 years.
J Edwards, Edwards, J., Bartlett, J.M.S., J. M. S. Bartlett   +3 more
core   +1 more source

MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner

Neoplasia: An International Journal for Oncology Research, 2016
PURPOSE: Increased murine double minute 2 (MDM2) expression, independent of p53 status, is associated with increased cancer-specific mortality for men with prostate cancer treated with radiotherapy.
Felix Y. Feng, Yu Zhang, Vishal Kothari, Joseph R. Evans, William C. Jackson, Wei Chen, Skyler B. Johnson, Connor Luczak, Shaomeng Wang, Daniel A. Hamstra   +9 more
doaj   +1 more source

Androgen Deprivation Therapy and Alzheimer's Disease [PDF]

Journal of Clinical Oncology, 2016
unmeasured or hidden confounders were present to put the hormonal treatment population at a disadvantage. For instance, hormonal treatment could have been used less critically in patients with mild symptoms of dementia or in those of lower socioeconomic status.
Michael, Froehner, Manfred P, Wirth
openaire   +2 more sources